PROCESSA PHARMACEUTICALS INC (PCSA)

Company Profile

Processa Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drug products for the treatment of serious medical conditions. The company is headquartered in Hanover Maryland, Maryland and currently employs 15 full-time employees. The company went IPO on 2013-10-07. The firm is focused on utilizing the Processa Regulatory Science Approach, including the principles associated with food and drug administration (FDA’s) project Optimus Oncology initiative and the related FDA Draft Guidance, in the development of next generation chemotherapy (NGC) oncology drug products. Its pipeline consists of three oncology drugs (NGC-Capecitabine, NGC-Gemcitabine and NGC-Irinotecan) and two non-oncology drugs (PCS12852 and PCS499). NGC-Capecitabine is an orally administered irreversible inhibitor of the enzyme dihydropyrimidine dehydrogenase (DPD). NGC-Gemcitabine is an oral analog of gemcitabine that is converted to its active metabolite by a different enzyme system than gemcitabine resulting in a positive response in gemcitabine patients as well as some gemcitabine treatment-resistant patients. NGC-Irinotecan is a prodrug of the active metabolite of irinotecan (SN-38).

Company Info

PROCESSA PHARMACEUTICALS INC

7380 Coca Cola Dr Ste 106

Hanover Maryland MARYLAND 21076

P: 14437763133

CEO: David Young

Employees: 15

Website: https://www.processapharmaceuticals.com/